GC-02. Resistance to anti-CD19 CAR T-cell therapy. Case report

Cellular Therapy and Transplantation

article

Alexandr A. Migas¹  Tatsiana V. Shman¹  Anna V. Klych¹  Elena S. Lukojko¹  Evgeniy V. Dmitriev¹  Lyudmila V. Movchan¹  Mikalai A. Katsin²  Inna V. Proleskovskaya¹  Olga V. Aleinikova³ 

[1] Belarusian Research Center for Pediatric Oncology;Vitebsk Regional Center of Clinical Oncology;Dmitry Rogachev National Research Center of Pediatric Hematology

关键词: Total body irradiation;    allo-HSCT;    children;    hemoblastoses;    radiation therapy.;   

DOI  :  10.18620/ctt-1866-8836-2022-11-3-1-132

学科分类：肿瘤学

来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf

【 摘 要 】

Primary resistance to CAR T-cell therapy occurs in 10-20% of pediatric B-ALL cases [PA Atilla, 2022]. Impaired functional activity of CAR T-cells and biological properties of leukemic cells are among the causes of described phenomenon. Anti-CD19 CAR T-cell therapy was carried out at Belarusian Research Center for Pediatric Oncology, Hematology and Immunology (BRCPOHI) for 8 B-ALL patients with one case proven to have primary resistance to the given therapy.

【 授权许可】

CC BY